Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.

He J, Shen D, Chung DU, Saxton RE, Whitelegge JP, Faull KF, Chang HR.

Int J Oncol. 2009 Oct;35(4):683-92.

PMID:
19724903
[PubMed - indexed for MEDLINE]
2.

Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma.

Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL Jr, Drake RR, Vlahou A.

Cancer. 2004 May 1;100(9):1814-22.

PMID:
15112261
[PubMed - indexed for MEDLINE]
Free Article
3.

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.

Bonneterre J, Révillion F, Desauw C, Blot E, Kramar A, Fournier C, Hornez L, Peyrat JP.

Oncol Rep. 2013 Jan;29(1):355-61. doi: 10.3892/or.2012.2090. Epub 2012 Oct 19.

PMID:
23117275
[PubMed - indexed for MEDLINE]
4.

Identification of potential markers related to neoadjuvant chemotherapy sensitivity of breast cancer by SELDI-TOF MS.

Zhang K, Yuan K, Wu H, Li Q, Wang Y, Chen S, Zhang L, Gu H, Fu R.

Appl Biochem Biotechnol. 2012 Feb;166(3):753-63. doi: 10.1007/s12010-011-9464-z. Epub 2011 Nov 30.

PMID:
22127810
[PubMed - indexed for MEDLINE]
5.

Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer.

Han M, Liu Q, Yu J, Zheng S.

Clin Chem Lab Med. 2010 Jun;48(6):863-7. doi: 10.1515/CCLM.2010.169.

PMID:
20345233
[PubMed - indexed for MEDLINE]
6.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ.

J Natl Cancer Inst. 2004 May 19;96(10):759-69.

PMID:
15150304
[PubMed - indexed for MEDLINE]
Free Article
7.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
[PubMed - indexed for MEDLINE]
Free Article
8.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

PMID:
20549829
[PubMed - indexed for MEDLINE]
Free Article
9.

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.

Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S.

Breast Cancer Res Treat. 2010 Nov;124(1):133-40. doi: 10.1007/s10549-010-1103-9. Epub 2010 Aug 10.

PMID:
20697801
[PubMed - indexed for MEDLINE]
10.

Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.

von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group.

J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. doi: 10.1093/jnci/djn085. Epub 2008 Apr 8.

PMID:
18398097
[PubMed - indexed for MEDLINE]
Free Article
11.

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].

Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.

Magy Onkol. 2009 Dec;53(4):335-43. doi: 10.1556/MOnkol.53.2009.4.2. Hungarian.

PMID:
20071305
[PubMed - indexed for MEDLINE]
Free Article
12.

Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.

Barros Filho MC, Katayama ML, Brentani H, Abreu AP, Barbosa EM, Oliveira CT, Góes JC, Brentani MM, Folgueira MA.

Braz J Med Biol Res. 2010 Dec;43(12):1225-31. Epub 2010 Nov 26.

PMID:
21103787
[PubMed - indexed for MEDLINE]
Free Article
13.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.

J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.

PMID:
20308670
[PubMed - indexed for MEDLINE]
Free Article
14.

Support vector machines coupled with proteomics approaches for detecting biomarkers predicting chemotherapy resistance in small cell lung cancer.

Han M, Dai J, Zhang Y, Lin Q, Jiang M, Xu X, Liu Q, Jia J.

Oncol Rep. 2012 Dec;28(6):2233-8. doi: 10.3892/or.2012.2037. Epub 2012 Sep 17.

PMID:
22992788
[PubMed - indexed for MEDLINE]
15.

Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.

Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R.

Breast Cancer Res. 2008;10(3):R48. doi: 10.1186/bcr2101. Epub 2008 May 29.

PMID:
18510725
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors.

Frati A, Chereau E, Coutant C, Bezu C, Antoine M, Chopier J, Daraï E, Uzan S, Gligorov J, Rouzier R.

Breast Cancer Res Treat. 2012 Apr;132(2):601-7. doi: 10.1007/s10549-011-1897-0. Epub 2011 Dec 9.

PMID:
22160638
[PubMed - indexed for MEDLINE]
17.

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.

Breast Cancer Res. 2008;10(2):R30. doi: 10.1186/bcr1989. Epub 2008 Apr 1.

PMID:
18380893
[PubMed - indexed for MEDLINE]
Free PMC Article
18.
19.

Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.

Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.

Zentralbl Gynakol. 2006 Apr;128(2):76-81.

PMID:
16673249
[PubMed - indexed for MEDLINE]
20.

Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.

Yu Z, Yu JK, Fang XF, Yuan Y, Shen H.

Hepatogastroenterology. 2013 Oct;60(127):1800-4.

PMID:
24624447
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk